Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE

Next Previous
Trial Profile

A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OCU 410 ST (Primary)
  • Indications Cone rod dystrophies; Retinitis pigmentosa; Stargardt disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GARDian; GARDian 1; GARDian3
  • Sponsors Ocugen

Most Recent Events

  • 30 Sep 2026 According to an Ocugen media release, data from this trial will be presented at upcoming scientific conferences.
  • 01 Apr 2026 Status changed from recruiting to active, no longer recruiting, according to an Ocugen media release.
  • 01 Apr 2026 According to an Ocugen media release, dosing has been successfully completed ahead of schedule. Trial enrollment and dosing completed (N=63) in less than nine months. Topline results expected in 2Q27 with BLA to follow by mid-2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top